论文部分内容阅读
在用a-CD3单抗和20U/ml rIL-2扩增FBL-3红白血病肿瘤细胞免疫的小鼠脾细胞,获取了具有高度杀瘤活性的、FBL-3特异性的T细胞的基础上,观察了a-CD4单抗对FBL-3特异性的T细胞的增殖、杀瘤活性及表型的影响.本研究采用四种不同的培养方案:(1)单独使用a-CD3单抗(CD3组);(2)单独使用20U/ml rIL-2(IL-2组);(3)使用a-CD3单抗48小时后,加入a-CD3单抗和20U/ml rIL-2(CD3+IL-2组);(4)a-CD3单抗和a-CD4单抗同时使用48小时后,加入a-CD3单抗、a-CD4单抗和20U/ml rIL-2(CD3+CD4+IL-2组).实验结果显示,CD3+IL-2组在20天培养过程中细胞扩增为590倍,在培养12天时对FBL-3的最大杀伤活性为83.6%;CD3+CD4+IL-2组在20天培养过程中细胞扩增为950倍,在培养12天时对FBL-3的最大杀伤活性
The mouse spleen cells immunized with ablocyte monoclonal antibody and 20 U/ml rIL-2 to amplify FBL-3 erythroleukemia tumor cells were obtained based on the highly tumorigenic activity of FBL-3 specific T cells. The effects of a-CD4 monoclonal antibody on the proliferation, tumoricidal activity and phenotype of FBL-3 specific T cells were investigated. Four different culture protocols were used in this study: (1) single use of a-CD3 monoclonal antibody ( CD3 group) (2) 20U/ml rIL-2 alone (IL-2 group); (3) 48 hours after a-CD3 mAb, a-CD3 mAb and 20U/ml rIL-2 (CD3) were added (+IL-2 group); (4) 48 hours after the simultaneous use of a-CD3 and a-CD4 monoclonal antibody, a-CD3 monoclonal antibody, a-CD4 mAb, and 20 U/ml rIL-2 (CD3+CD4) were added. +IL-2 group). Experimental results showed that the CD3+IL-2 group had 590-fold cell expansion during the 20-day culture period, and the maximum killing activity against FBL-3 was 83.6% at 12 days of culture; CD3+CD4+ In the IL-2 group, the cell expansion was 950-fold during the 20-day culture and the maximum killing activity against FBL-3 was observed at 12 days of culture.